Dilon Technologies, a global leader in medical devices for biosurgery and breast cancer treatment and diagnosis, announced a $9 million growth capital investment from JGB Management. The investment will support Dilon’s continued double-digit revenue growth and operational scaling.
Dilon Technologies has built a robust presence in surgical settings with a portfolio of products that improve clinical outcomes.
Related: AIATELLA raises €2m for AI-powered cardiovascular imaging tools
“We are proud to partner with JGB as we advance our mission to deliver evidence-based surgical solutions worldwide,” said George Makhoul, CEO of Dilon Technologies. “This funding empowers us to continue delivering best-in-class innovations that improve patient care.”
HEMOBLAST Bellows is a groundbreaking advanced hemostatic agent used in a wide range of surgeries—including cardiac, general, and orthopedic procedures. It remains the only FDA-approved product specifically indicated for the control of minimal, mild, and moderate bleeding. Now utilized in several hundred U.S. hospitals, HEMOBLAST Bellows continues to redefine standards in surgical hemostasis.
Another key product, MarginProbe an in-surgery, real-time breast cancer margin assessment device. It enables surgeons to assess lumpectomy margins intraoperatively, significantly reducing the need for repeat surgeries. Clinical studies show MarginProbe reduces re-excision rates by 25% to 80%. A 2025 study published in The American Surgeon Journal highlighted a 42% reduction in re-excision for patients with DCIS. A next-generation version of the device has been submitted to the FDA, with approval anticipated by year-end.
Dilon’s Navigator Gamma Probe product line, a market-leading tool for radio-guided lymphatic mapping and tumour localisation, continues to perform strongly worldwide. A new, enhanced version is expected to launch by late 2025.
“We are pleased to partner with Dilon Technologies to help them grow in their mission to provide surgical solutions worldwide,” said Brett Cohen, CEO of JGB Management Inc.
